



# CLINICAL CANCER GENOMICS COMMUNITY OF PRACTICE

CITY OF HOPE DIVISION OF CLINICAL CANCER GENOMICS

This recording is provided for review purposes only and viewing *does not* substitute attendance.

Due to HIPAA, please **DO NOT** attempt to distribute this document or the corresponding recording.

## \*CHAT LOG TIMECODES MAY NOT ALIGN WITH RECORDING\*

02:09:42 Clinical Cancer Genetics: CME code for this session: PAVMEH  
02:12:48 Dara McKinley FNP-C AGN-BC: would you test sister and/or children  
02:12:50 Cindy Snyder DNP, ACGN, FNP-C. CBCN: Would tumor profiling of pancreas cancer be of any use for clarification?  
02:13:23 Elyssa Zukin: Not sure if this was mentioned already, but since Ambry's classification was from 2021, I might contact them directly and see if they still classify it as pathogenic/likely pathogenic.  
02:14:56 Steve Gruber: I agree with pre-surgical plasma metanephrine and normetanephrine recommendation...excellent idea. Then to clarify VUS meaning I would see whether Invitae is offering family testing  
02:15:33 Lauren Gima (she/her): @Dara, without an informative result, I wouldn't necessarily recommend testing other FDR for the VUS outside of possible lab-recommended tracking studies  
02:15:51 Steve Gruber: I agree with Lauren  
02:16:55 Lauren Gima (she/her): @Cindy, b/c PDAC is not currently known to be related to SDHC PVs, I don't know that tumor profiling would help in this case  
02:17:23 Kristina Tanner: @cindy: Tempus testing didn't have anything huge show up  
02:17:54 Karen Collins: Does anyone have a form and routinely ask patients in the case of their death if they would want their family to be able to access the test results?  
02:18:04 COH - Suzie Shehayeb (she/her): You definitely tested the most informative person in this family Kris!  
02:18:10 Clinical Cancer Genetics: CME code for this session: PAVMEH  
02:19:35 COH - Gloria Nunez: Again, the CME code is for alumni and other, but not for IC 2023 participants.  
02:20:38 COH - Suzie Shehayeb (she/her): @Karen, for the US at least, the form would likely be dependent on your institution and local/state laws.  
02:21:15 Karen Collins: Replying to "@Karen, for the US a..." okay. Thank you  
02:21:50 COH - Suzie Shehayeb (she/her): Sure!  
02:22:19 Duveen Sturgeon: I would test the mother.  
02:22:59 COH - Suzie Shehayeb (she/her): She definitely would need a panel anyway Duveen!  
02:25:33 Allison Jay: can someone please post the code thank you!  
02:25:45 Clinical Cancer Genetics: CME code for this session: PAVMEH  
02:25:51 Allison Jay: thank u!!  
02:26:10 Carrie Thompson: If it is AFAP and she had a child, would you recommend liver surveillance?  
02:26:13 City of Hope - PopSci Conference Room: Definitely test them  
02:27:31 Jennifer Diaz: What about a 68 y/o F with no FH of colon cancer, has had a couple of colonoscopies showing numerous/>50 polyps(reportedly adenomas), father supposedly had a few colon polyps at 40, patient's multigene testing neg. Pt is getting a total colectomy.  
Would you manage her and her family like they have APC?  
02:28:37 Bitu Nehoray: @Jennifer that would be a good case to present and getting records to confirm the polyp types would be important, too  
02:29:24 Jennifer Diaz: Ok, thanks Bitu.

02:30:40 Dara McKinley FNP-C AGN-BC: I have a question re: AFAP vs. FAP. I have a patient who has AFAP and his daughter was tested with same mutation. I don't follow her any longer. She is out of touch with her children live with my patient. If the grandfather is AFAP then the daughter is too correct? Based on location on the APC gene

02:36:37 Christina Rybak: comes up more in prenatal I think

02:36:39 Christina Rybak: yep

02:38:07 Robbin Palmer: Have you researched whether there are any experts in dped genetics to consult?

02:38:50 Christina Rybak: super interesting

02:40:15 Robbin Palmer: Is genetic testing for isolated ped neuroblastoma routine? What about FHx of isolated neuroblastoma??

02:40:54 Jennifer Diaz: Fascinating! I can listen to these case studies all day 😊

02:41:37 Clinical Cancer Genetics: CME code for this session: PAVMEH

02:41:46 Christina Rybak: thank YOU!

02:41:59 Kaila Wilson: <https://aacrjournals.org/clincancerres/article/23/13/e98/80129/Retinoblastoma-and-Neuroblastoma-Predisposition>

02:42:02 COH - John Luna: Junne\_Kamihara@dfci.harvard.edu

02:42:46 Kaila Wilson: This is a paper by Dr. Kamihara that Bitia wanted to pass along :)

02:43:28 COH - Suzie Shehayeb (she/her): Thanks Kaila and John!

02:44:37 Robbin Palmer: Dr. Mullance, what is recommended surveillance/management plan?

02:46:10 Kathleen Mott: Did you find that sleep apnea is associated with the mutation?

02:47:39 Clinical Cancer Genetics: CME code for this session: PAVMEH

02:47:47 COH - Suzie Shehayeb (she/her): Great job with this case Dr. Mullane!